FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:772 August 14, 2008 Number 7

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

(Current Clinical Oncology.) Edited by Richard G. Pestell and Marja T. Nevalainen. 455 pp., illustrated. Totowa, NJ, Humana Press, 2008. $139 (cloth); $99 (paper). ISBN 978-1-58829-741-9 (cloth); 978-1-60327-518-7 (paper).

More than 218,000 new cases of prostate cancer are diagnosed every year in the United States. Great improvements in diagnosis and treatment have been made over the past two decades, but because prostate cancer has marked variability in its rate of progression, it remains a challenge for researchers attempting to unravel its heterogeneous character.

In this detailed and up-to-date book, leaders in prostate cancer research review the current knowledge of genetic pathways and major molecular aberrations involved in prostate cancer as well as the treatment of the disease. The literature is thoroughly reviewed — some chapters contain more than 200 . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.